Probatebeta
Target

TNFRSF9

Tumor necrosis factor receptor superfamily member 9

As of the edition of 20 October 2026, TNFRSF9 (tumor necrosis factor receptor superfamily member 9, UniProt Q07011) has 16 drugs tested at it and 15 companies on the list, 5 on route A and 0 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q07011
How well studied
Biology documented; no tool compounds or approved drug yet
Where it sits in the cell
At a membrane
Solved structures
14
Disease areas
Cancer; Skin and connective tissue; Blood and lymph; Immune system; Lungs and airways; Urinary and reproductive; Digestive system; Pregnancy and women's health
Registered trials of its drugs
68

Drugs at this target

StatusCount
Active7
Went quiet1
Stopped3
Status not established5
Total16
DrugStatusFurthest phaseUS protection
UtomilumabActivePhase 3none listed
UrelumabStoppedPhase 2none listed
ADG-106StoppedPhase 2none listed
AcasunlimabActivePhase 3none listed
CTX-471ActivePhase 2none listed
GEN1042ActivePhase 2none listed
BT7480ActivePhase 2none listed
CB307Status not establishedPhase 1none listed
ES101StoppedPhase 2none listed
HLX35Status not establishedPhase 1none listed
YH004Status not establishedPhase 1none listed
AP203ActivePhase 2none listed

12 of 16 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Engaged6
Undetermined4
Total on the list15
Three companies on route A or B, with the route only
CompanyRoute
Bristol Myers SquibbRoute A
Gilead SciencesRoute A
AdageneRoute A

The other 12 companies at TNFRSF9

In the product

15 companies in all; 12 are not named here, and no score is.

See the 15 companies at TNFRSF9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at TNFRSF9

Other targets in cancer